NanoComposix expands its full-service lateral flow assay development services using novel ultra-sensitive nanoparticle reporters, covalent binding chemistry, and quantitative smartphone-based reader technologies for better lateral flow assays
San Diego, CA, July 14, 2017 – nanoComposix, Inc., a global supplier of the widest variety of precisely engineered, highly characterized nanoparticles, has expanded its lateral flow services to provide full-service lateral flow assay development solutions for its medical device customers. NanoComposix’s development team solves sensitivity, sample matrix, and quantification challenges with new ultra-sensitive nanoparticle probes, covalent binding chemistry, and new advances in quantitative smartphone based reader technologies.
“The fundamental limits of sensitivity in lateral flow diagnostics are dictated by the reporter nanoparticle” said Dr. Steven Oldenburg, Founder and CEO of nanoComposix. “With more than a decade of experience building precisely engineered and highly characterized nanomaterials for thousands of customers worldwide, nanoComposix is uniquely positioned to provide the improved particles and chemistry necessary for ultrasensitive, rapid, quantitative, point of care lateral flow diagnostic tests.”
NanoComposix’s proprietary gold nanoshells provide up to a 20-fold increase in sensitivity compared to 40 nm diameter gold nanospheres enabling lateral flow assay tests that were previously not possible. Unique “bare” gold nanoparticles with a highly displaceable surface optimized for passive adsorption generate stable and reproducible conjugates. Covalent conjugation chemistry improves conjugate stability in a variety of matrices, provides greater control over per particle antibody loading improving conjugate reproducibility, and, due to higher antibody binding efficiency, can reduce the antibody reagent cost of the assay. NanoComposix’s full service assay development services leverages the company’s unique expertise to provide rapid development of ISO13485 compliant assays. Services include feasibility, assay design, antibody pair selection, full strip optimization, prototype cassette design, verification and validation, and transfer to full scale production. For assay quantification, nanoComposix provides multiple reader options with an emphasis on cell phone-based reader technology.
NanoComposix is a San Diego, California company with the world’s largest variety of metal nanoparticles for biomedical applications in life science, diagnostics, and therapeutics. GMP and ISO13485 compliant manufacturing methods produce precisely engineered and highly characterized nanoparticles that provide high levels of consistency and performance. Through the establishment of open and collaborative relationships, we rapidly generate innovative solutions to our clients’ most challenging R&D problems. NanoComposix markets their products directly and through distributors and licensing partners worldwide.